Progress in Gaucher’s Disease: Comorbidities and Strategies

BALTIMORE, MD—February 3, 2015—Med-IQ, an ACCME-accredited provider of continuing medical education (CME), will be hosting a certified CME dinner satellite symposium on the management of Gaucher’s disease (GD) at the 11th Annual WORLDSymposium™.

GD is a rare lysosomal storage disorder that is often associated with other diseases. Although the understanding of this rare genetic disorder has increased in recent years, certain aspects of the disease still remain unclear, like the relationship of GD to Parkinson’s disease (PD), pulmonary issues, and certain types of cancers.

During this live event, Advancing the Management of Gaucher’s Disease, a faculty panel will review key topics in GD, including the risk and causes of PD and malignancies associated with type 1 GD. The interactive event will also review the benefits and limitations of available medications and emerging treatment strategies for neuronopathic GD, and important factors for selecting patients for treatment, such as comorbid conditions, pharmacogenetics, and concomitant medications.

“The introduction of new therapies has provided a means to change the clinical course and outcomes for many patients with type 1 GD” says T. Andrew Burrow, MD, assistant professor of clinical pediatrics at the University of Cincinnati College of Medicine. “This symposium will also explore strategies for overcoming the unmet medical needs including risks of developing associated diseases such as PD and cancer.”

This free CME dinner meeting will be held in Orlando as a satellite symposium at the 11th Annual WORLDSymposium™ on Wednesday, February 11, 2015 from 6:45 PM to 8:45 PM at the Hyatt Regency Orlando. Clinicians are invited to visit www.Med-IQ.com/a836, call (toll-free) 866 858 7434, or e-mail info@med-iq.com for more information.

This Satellite Symposium is not part of the official WORLDSymposium™ 2015 program, and WORLDSymposium™ 2015 does not approve or endorse any commercial products or services discussed during the Symposium or offered for sale by the corporate supporter of the Symposium. This symposium is not approved for CME by WORLDSymposium™ 2015. This Symposium is approved for CME credit by Med-IQ.

This activity is approved for AMA PRA Category 1 Credit™.

This activity is supported by an educational grant from Genzyme, a Sanofi company.

About Med-IQ

Med-IQ, America's most respected provider of continuing medical education (CME), inspires healthcare professionals through award-winning activities that deliver sophisticated outcomes-based educational designs with measurable results in professional competence and performance. Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the California Board of Registered Nursing (CBRN), and the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing medical education to physicians, nurses, and pharmacists, respectively.

Med-IQ, a leader in the development of performance improvement (PI) and quality improvement (QI) CME initiatives, has been recognized by the Alliance for Continuing Education in the Health Professions for our excellence in CE research (William Campbell Felch Award 2013, 2011), educational collaborations (2013), outstanding CME outcomes assessment (2012), and exceptional leadership (Leadership Award 2013, President’s Award 2012). To learn more about Med-IQ, visit www.Med-IQ.com, like us on Facebook, follow us on Twitter, and connect with us on LinkedIn.

For more information, contact:

Amy Caswell
Senior Audience Development Manager
866 858 7434
info@med-iq.com


Med-IQ.
Inspiring Medical Education.